Profound Medical Corp.
PROF
$6.19
-$0.11-1.75%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.68M | 1.22M | 650.00K | 820.00K | 1.49M |
| Total Other Revenue | 2.30M | 4.07M | 1.56M | 1.80M | 2.69M |
| Total Revenue | 5.98M | 5.29M | 2.21M | 2.62M | 4.18M |
| Cost of Revenue | 1.99M | 1.36M | 593.00K | 768.00K | 1.21M |
| Gross Profit | 3.99M | 3.93M | 1.62M | 1.85M | 2.96M |
| SG&A Expenses | 7.09M | 7.43M | 9.33M | 8.21M | 6.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.35M | 14.20M | 16.02M | 13.79M | 12.52M |
| Operating Income | -7.37M | -8.91M | -13.81M | -11.17M | -8.35M |
| Income Before Tax | -8.15M | -7.86M | -15.63M | -10.68M | -5.19M |
| Income Tax Expenses | 26.00K | 121.00K | 64.00K | 41.00K | -238.00K |
| Earnings from Continuing Operations | -8.18M | -7.98M | -15.70M | -10.72M | -4.95M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.18M | -7.98M | -15.70M | -10.72M | -4.95M |
| EBIT | -7.37M | -8.91M | -13.81M | -11.17M | -8.35M |
| EBITDA | -7.26M | -8.77M | -13.67M | -11.00M | -8.11M |
| EPS Basic | -0.27 | -0.27 | -0.52 | -0.36 | -0.19 |
| Normalized Basic EPS | -0.17 | -0.16 | -0.33 | -0.22 | -0.13 |
| EPS Diluted | -0.27 | -0.27 | -0.52 | -0.36 | -0.19 |
| Normalized Diluted EPS | -0.17 | -0.16 | -0.33 | -0.22 | -0.13 |
| Average Basic Shares Outstanding | 30.57M | 30.10M | 30.05M | 30.04M | 25.77M |
| Average Diluted Shares Outstanding | 30.57M | 30.10M | 30.05M | 30.04M | 25.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |